Clinical Trials Logo

Premenopausal clinical trials

View clinical trials related to Premenopausal.

Filter by:
  • None
  • Page 1

NCT ID: NCT03505736 Completed - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer

Start date: June 21, 2018
Phase:
Study type: Observational

This pilot trial studies how well a stress test works in detecting heart damage in premenopausal women with stage I-III breast cancer. Giving a stress test with adenosine or regadenoson and cardiovascular magnetic resonance imaging may help doctors detect heart damage caused by breast cancer treatments including chemotherapy and aromatase inhibitors.

NCT ID: NCT03448003 Active, not recruiting - Premenopausal Clinical Trials

Comprehensive Lifestyle Change To Prevent Breast Cancer

Start date: April 4, 2019
Phase: N/A
Study type: Interventional

This trial studies how well comprehensive lifestyle change works in preventing patients from breast cancer. A program including dietary recommendations, physical activity, stress management and mindfulness training, learning sleep hygiene techniques, and behavioral counseling in addition to social support may help patients who may be at risk for breast cancer.

NCT ID: NCT02760849 Active, not recruiting - Clinical trials for Hereditary Breast and Ovarian Cancer Syndrome

Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations

Start date: May 2, 2016
Phase: N/A
Study type: Interventional

This phase II trial studies how well surgery works in preventing ovarian cancer in patients with genetic mutations at risk of ovarian cancer. Risk reducing salpingo oophorectomy (RRSO) is surgery to remove the fallopian tubes and ovaries at the same time. Interval salpingectomy with delayed oophorectomy (ISDO) is surgery to remove the fallopian tubes. It is not known whether ISDO works better than RRSO at lowering risk of ovarian cancer and improving the sexual function and psychosocial well-being in patients with genetic mutation.

NCT ID: NCT02734823 Withdrawn - Clinical trials for Gastrointestinal Stromal Tumor

Long Term Effects of Tyrosine Kinase Inhibitor Therapy on Ovarian Reserve and Fertility in Patients With Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumor

Start date: March 1, 2016
Phase:
Study type: Observational

This pilot research trial studies the long term effects of tyrosine kinase inhibitor therapy on ovarian reserve and fertility in patients with chronic myeloid leukemia or gastrointestinal stromal tumor. Studying ovary imaging, ovarian reserve markers, and hormone levels from patients receiving tyrosine kinase inhibitor therapy may help doctors learn more about the effects of tyrosine kinase inhibitor therapy on ovarian function and fertility.

NCT ID: NCT02152943 Completed - Clinical trials for Advanced Malignant Solid Neoplasm

Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients

Start date: July 17, 2014
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of everolimus and trastuzumab when given together with letrozole in treating patients with hormone receptor-positive and human epidermal growth factor (EGF) receptor 2 (HER2)-positive breast cancer or other solid tumors that have spread to other places in the body. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by blocking the use of estrogen by tumor cells. Immunotherapy with monoclonal antibodies, such as trastuzumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving everolimus, letrozole, and trastuzumab together may be a better treatment for breast cancer and other solid tumors than everolimus alone.

NCT ID: NCT01842217 Terminated - Postmenopausal Clinical Trials

Validation of [18F]FES for Imaging of Brain Estrogen Receptors

Start date: November 2013
Phase: N/A
Study type: Interventional

Validation of [18F]-FES for imaging of estrogen receptors in the brain The primary objective of the study is to determine if [18F]-FES Positron Emission Tomography (PET) can be used to quantify the estrogen receptor expression in the human brain.